Compare Adaptive Biotechnologies Corp (ADPT) vs Ishares Msci Thailand Etf (THD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Ishares Msci Thailand Etf — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Ishares Msci Thailand Etf trades at $70.3. Which is the better fit depends on your goals.
| ADPT | THD | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $22.37 | $75.05 |
52-Week Low | $10.24 | $51.15 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
THD, the iShares MSCI Thailand ETF, trades at $72.91, up 1.8% on the day, with a bullish technical signal from moving averages and a neutral reading from oscillators. The ETF offers exposure to Thai equities, with a declared dividend of $1.71 for H1-2026. Recent news highlights a significant increase in short interest and ongoing assessments of Thailand's economic policy environment.
The outlook for THD is mixed, with attractive valuations for contrarian investors noted by Seeking Alpha (2026-04-12) but tempered by historical underperformance and political volatility. Key risks include macroeconomic sensitivity to regional central bank policies and geopolitical events, while the primary opportunity lies in a potential rebound if market sentiment on Thailand improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →
